Stavudine sodium
(Synonyms: 司他夫定钠; d4T sodium) 目录号 : GC37690An inhibitor of HIV reverse transcriptase
Cas No.:134624-73-0
Sample solution is provided at 25 µL, 10mM.
Stavudine is an inhibitor of HIV reverse transcriptase and a derivative of the nucleoside thymidine .1 It inhibits HIV-1 replication in human peripheral blood mononuclear cells (PBMCs; EC50 = 8.8 nM). Stavudine reduces the synthesis of HIV-specific antigen in MT-4 cells when used at concentrations ranging from 0.1 to 10 ?g/ml and reduces HIV-induced plaque formation in MT-4 cells at 0.05 ?g/ml.2 It reduces plasma- and cell-associated viral load in macaques infected with a highly pathogenic isolate of HIV-2.3 Stavudine induces sustained hind paw mechanical allodynia in a rat model of antiretroviral toxic neuropathy (ATN) when administered at a dose of 75 mg/kg twice weekly for five consecutive doses for a cumulative dose of 375 mg/kg.4 Formulations containing stavudine, in combination with other antiretrovirals, have been used in the treatment of HIV-1 infection.
1.Lin, T.-S., Schinazi, R.F., and Prusoff, W.H.Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virusBiochem. Pharmacol.36(17)2713-2718(1987) 2.Hamamoto, Y., Nakashima, H., Matsui, T., et al.Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virusAntimicrob. Agents Chemother.31(6)907-910(1987) 3.Watson, A., McClure, J., Ranchalis, J., et al.Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaquesAIDS Res. Hum. Retroviruses13(16)1375-1381(1997) 4.Kuo, A., Nicholson, J.R., Corradini, L., et al.Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methodsInflammopharmacology27(2)387-396(2019)
Cas No. | 134624-73-0 | SDF | |
别名 | 司他夫定钠; d4T sodium | ||
Canonical SMILES | [O-]C[C@H]1O[C@@H](N2C=C(C)C(NC2=O)=O)C=C1.[Na+] | ||
分子式 | C10H11N2NaO4 | 分子量 | 246.2 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0617 mL | 20.3087 mL | 40.6174 mL |
5 mM | 0.8123 mL | 4.0617 mL | 8.1235 mL |
10 mM | 0.4062 mL | 2.0309 mL | 4.0617 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet